[{"id":"ddcf471d-cc99-4126-ad7e-d3bd66cbde07","acronym":"","url":"https://clinicaltrials.gov/study/NCT03164772","created_at":"2021-01-18T15:36:10.900Z","updated_at":"2025-02-25T14:58:07.097Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC","source_id_and_acronym":"NCT03164772","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • BI 1361849 • self-amplifying RNA cancer vaccine"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/20/2017","start_date":" 12/20/2017","primary_txt":" Primary completion: 10/29/2021","primary_completion_date":" 10/29/2021","study_txt":" Completion: 10/29/2021","study_completion_date":" 10/29/2021","last_update_posted":"2022-10-10"}]